News
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer
Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying
Pfizer to Acquire Trillium Therapeutics Inc.
Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and
Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer
Agilent Technologies Inc. (NYSE: A) announces that researchers at the Indian Institute of Technology Bombay in India and the QIMR Berghofer Medical Research Institute in Australia have developed a
Agilent Reports Third-Quarter Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.59 billion for the third quarter ended July 31, 2021, an increase of 26% compared to the third quarter of 2020 and up 21% on a core(
Pfizer Prices $1.0 Billion Sustainability Bond
Pfizer Inc. (NYSE: PFE) today announced the pricing of a sustainability bond of $1,000,000,000 in aggregate principal amount of 1.750% senior notes due 2031.
The closing of the offering is
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TICOVAC™ (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in
Quidel Reports Second Quarter 2021 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
Humana Highlights Commitment to Addressing Health Equity in 2020 Corporate Responsibility Report
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today released its 2020 Corporate Social Responsibility (CSR) report. As outlined in the report, Humana details
Agilent Earns 2021 Great Place to Work Certification in the U.S.
Agilent Technologies Inc. (NYSE: A) today announced that it has been certified as a Great Place to Work in the U.S., a prestigious independent recognition based entirely on employee feedback about
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease
Agilent Announces Target Enrichment Manufacturing Facility in China
Agilent Technologies Inc. (NYSE: A) today announced that is has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China.
Agilent is a leading provider
Dexcom Reports Second Quarter 2021 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2021.
Second Quarter 2021 Financial Highlights:
-
Revenue grew 32% versus the same
Illumina to Webcast Upcoming Investor Conference
Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
-
UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021
Humana Ranks #1 for Customer Satisfaction for Mail Order for Four Consecutive Years in J.D. Power U.S. Pharmacy Study
Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), received the highest ranking in Mail Order Pharmacy customer satisfaction for the fourth year in a row in the J.D. Power 2021 U.S. Pharmacy
Agilent Early Career Professor Award Presented to Jason H. Yang
Agilent Technologies Inc. (NYSE: A) today announced that Jason H. Yang, Ph.D., has received the 2021 Agilent Early Career Professor Award. Dr. Yang is an assistant professor of Microbiology
PFIZER REPORTS SECOND-QUARTER 2021 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) driven by its updated expectations for contributions
Clinical Utility of ALK Fusion Detection by Liquid Biopsy
Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled "Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and
Quidel Announces Agreement With Beckman Coulter That Terminates Ongoing Litigation and Transitions BNP Business to Beckman Coulter
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its entry into
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses
Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase
Illumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection.
“This acquisition is procompetitive, and we have
Agilent Technologies Celebrates More than 20 Years of Sustainable Progress
Agilent Technologies, Inc. (NYSE: A) today issued its 21st annual Corporate Social Responsibility (CSR) report. The report highlights the company’s progress in critical environmental, social and
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that it will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the
Agilent to Webcast Third-Quarter Fiscal Year 2021 Financial Results Presentation
Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, August 17. The company will host a live webcast of its